Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 December 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Treatment scale-up to achieve global HCV incidence and mortality elimination targets

The latest issue of Gut developed a cost-effectiveness model to achieve global HCV incidence and mortality elimination targets.

News image

The WHO's draft HCV elimination targets propose an 80% reduction in incidence and a 65% reduction in HCV-related deaths by 2030.

Dr Nick Scott and colleagues estimated the treatment scale-up required and cost-effectiveness of reaching these targets among injecting drug use-acquired infections using Australian disease estimates.

A mathematical model of HCV transmission, liver disease progression and treatment among current and former people who inject drugs.

Treatment scale-up and the most efficient allocation to priority groups were determined.

5662 courses per year were required, prioritized to patients with advanced liver disease, to reach the mortality target
Gut

Total healthcare and treatment costs, quality-adjusted life years, and incremental cost-effectiveness ratios compared with inaction were calculated.

The research team found that 5662 courses per year were required, prioritized to patients with advanced liver disease, to reach the mortality target.

The researchers noted that 4725 courses per year were required, prioritized to people who inject drugs, to reach the incidence target.

The team observed that this also achieved the mortality target, but to avoid clinically unacceptable HCV-related deaths an additional 5564 treatments per year were required for 5 years for patients with advanced liver disease.

Achieving both targets in this way cost $A4.6 billion more than inaction, but gained 184,000 quality-adjusted life years, giving an incremental cost-effectiveness ratio of $A25,121 per quality-adjusted life year gained.

Dr Scott's team commented, "Achieving WHO elimination targets with treatment scale-up is likely to be cost-effective, based on Australian HCV burden and demographics."

"Reducing incidence should be a priority to achieve both WHO elimination goals in the long-term."

Gut 2017;66:1507-1515
31 July 2017

Go to top of page Email this page Email this page to a colleague

 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 14 December 2017 
Reliability of the IBD index
 13 December 2017 
Tryptophan metabolism and IBD activity
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Management of abnormal liver blood tests
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 05 December 2017 
Childhood obesity into adulthood
 05 December 2017 
CT imaging for acute diverticulitis
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 04 December 2017 
Neoadjuvant chemoradiation for locally advanced rectal cancer
 04 December 2017 
Physical activity and Barrett’s esophagus
 04 December 2017 
Alcohol abstinence and alcoholic hepatitis
 01 December 2017 
Therapeutic drug monitoring in IBD
 01 December 2017 
Insulin therapy and liver cancer among diabetics
 01 December 2017 
Family burden of pediatric Crohn's in the USA
 30 November 2017 
Anastomotic leak after repeat intestinal resection in Crohn’s
 30 November 2017 
Oral capsule– vs colonoscopy-delivered fecal microbiota transplant
 30 November 2017 
Sessile serrated polyps and H. pylori in the USA
 29 November 2017 
Predicting mortality after colectomy for C. diff
 29 November 2017 
Obesity and cancer risk
 28 November 2017 
Surgical treatment delays and colon cancer survival
 28 November 2017 
Celiac disease screening in adult first-degree relatives
 28 November 2017 
Electronic health record alert in primary care in Hep C
 27 November 2017 
Questionnaire fore chronic constipation
 27 November 2017 
Challenges in measuring the affordability of US health care
 27 November 2017 
Early readmission in IBD patients
 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Predicting microscopic colitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us